The development and production of small molecule chemical drugs usually involves many complex steps, and the synthesis and production of small molecule chemical drugs require specialized equipment and technology. CDMO (Contract Development and Manufacturing Organization) is an organization that provides outsourcing services to pharmaceutical companies. It can provide a range of services from drug development to production.
The global Small Molecule Chemical Drug CDMO market was valued at US$ 47400 million in 2023 and is anticipated to reach US$ 103030 million by 2030, witnessing a CAGR of 12.0% during the forecast period 2024-2030.
North American market for Small Molecule Chemical Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Small Molecule Chemical Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Small Molecule Chemical Drug CDMO in Clinical Stage Projects is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Small Molecule Chemical Drug CDMO include Haixiang Pharmaceutical, Innovent Biologics, Betta Pharmaceuticals, Jiuzhou Pharmaceutical, Puluo Pharmaceutical, Menohua, Tianyu shares, Aoxiang Pharmaceutical and Hetero, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Small Molecule Chemical Drug CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecule Chemical Drug CDMO.
Report Scope
The Small Molecule Chemical Drug CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Molecule Chemical Drug CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Molecule Chemical Drug CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Haixiang Pharmaceutical
Innovent Biologics
Betta Pharmaceuticals
Jiuzhou Pharmaceutical
Puluo Pharmaceutical
Menohua
Tianyu shares
Aoxiang Pharmaceutical
Hetero
CellMark
R&D Systems
Porton Pharmaceuticals
Kai Laiying
Smart Life
Notai Biotech
Aurobindo Pharma
Lonza Group
Catalent Inc.
Recipharm AB
Jubilant Pharmova Ltd
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource
Baxter International Inc.
Segment by Type
Human Medicine
Veterinary Medicine
Segment by Application
Clinical Stage Projects
Commercialization Stage Projects
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecule Chemical Drug CDMO companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Human Medicine
1.2.3 Veterinary Medicine
1.3 麻豆原创 by Application
1.3.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinical Stage Projects
1.3.3 Commercialization Stage Projects
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Perspective (2019-2030)
2.2 Small Molecule Chemical Drug CDMO Growth Trends by Region
2.2.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Molecule Chemical Drug CDMO Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Small Molecule Chemical Drug CDMO Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Small Molecule Chemical Drug CDMO 麻豆原创 Dynamics
2.3.1 Small Molecule Chemical Drug CDMO Industry Trends
2.3.2 Small Molecule Chemical Drug CDMO 麻豆原创 Drivers
2.3.3 Small Molecule Chemical Drug CDMO 麻豆原创 Challenges
2.3.4 Small Molecule Chemical Drug CDMO 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Molecule Chemical Drug CDMO Players by Revenue
3.1.1 Global Top Small Molecule Chemical Drug CDMO Players by Revenue (2019-2024)
3.1.2 Global Small Molecule Chemical Drug CDMO Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Small Molecule Chemical Drug CDMO 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Small Molecule Chemical Drug CDMO Revenue
3.4 Global Small Molecule Chemical Drug CDMO 麻豆原创 Concentration Ratio
3.4.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Molecule Chemical Drug CDMO Revenue in 2023
3.5 Small Molecule Chemical Drug CDMO Key Players Head office and Area Served
3.6 Key Players Small Molecule Chemical Drug CDMO Product Solution and Service
3.7 Date of Enter into Small Molecule Chemical Drug CDMO 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Molecule Chemical Drug CDMO Breakdown Data by Type
4.1 Global Small Molecule Chemical Drug CDMO Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Small Molecule Chemical Drug CDMO Forecasted 麻豆原创 Size by Type (2025-2030)
5 Small Molecule Chemical Drug CDMO Breakdown Data by Application
5.1 Global Small Molecule Chemical Drug CDMO Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Small Molecule Chemical Drug CDMO Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Small Molecule Chemical Drug CDMO 麻豆原创 Size (2019-2030)
6.2 North America Small Molecule Chemical Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2019-2024)
6.4 North America Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size (2019-2030)
7.2 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2019-2024)
7.4 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Molecule Chemical Drug CDMO 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Small Molecule Chemical Drug CDMO 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Small Molecule Chemical Drug CDMO 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Small Molecule Chemical Drug CDMO 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Molecule Chemical Drug CDMO 麻豆原创 Size (2019-2030)
9.2 Latin America Small Molecule Chemical Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Haixiang Pharmaceutical
11.1.1 Haixiang Pharmaceutical Company Detail
11.1.2 Haixiang Pharmaceutical Business Overview
11.1.3 Haixiang Pharmaceutical Small Molecule Chemical Drug CDMO Introduction
11.1.4 Haixiang Pharmaceutical Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.1.5 Haixiang Pharmaceutical Recent Development
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Detail
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics Small Molecule Chemical Drug CDMO Introduction
11.2.4 Innovent Biologics Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.2.5 Innovent Biologics Recent Development
11.3 Betta Pharmaceuticals
11.3.1 Betta Pharmaceuticals Company Detail
11.3.2 Betta Pharmaceuticals Business Overview
11.3.3 Betta Pharmaceuticals Small Molecule Chemical Drug CDMO Introduction
11.3.4 Betta Pharmaceuticals Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.3.5 Betta Pharmaceuticals Recent Development
11.4 Jiuzhou Pharmaceutical
11.4.1 Jiuzhou Pharmaceutical Company Detail
11.4.2 Jiuzhou Pharmaceutical Business Overview
11.4.3 Jiuzhou Pharmaceutical Small Molecule Chemical Drug CDMO Introduction
11.4.4 Jiuzhou Pharmaceutical Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.4.5 Jiuzhou Pharmaceutical Recent Development
11.5 Puluo Pharmaceutical
11.5.1 Puluo Pharmaceutical Company Detail
11.5.2 Puluo Pharmaceutical Business Overview
11.5.3 Puluo Pharmaceutical Small Molecule Chemical Drug CDMO Introduction
11.5.4 Puluo Pharmaceutical Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.5.5 Puluo Pharmaceutical Recent Development
11.6 Menohua
11.6.1 Menohua Company Detail
11.6.2 Menohua Business Overview
11.6.3 Menohua Small Molecule Chemical Drug CDMO Introduction
11.6.4 Menohua Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.6.5 Menohua Recent Development
11.7 Tianyu shares
11.7.1 Tianyu shares Company Detail
11.7.2 Tianyu shares Business Overview
11.7.3 Tianyu shares Small Molecule Chemical Drug CDMO Introduction
11.7.4 Tianyu shares Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.7.5 Tianyu shares Recent Development
11.8 Aoxiang Pharmaceutical
11.8.1 Aoxiang Pharmaceutical Company Detail
11.8.2 Aoxiang Pharmaceutical Business Overview
11.8.3 Aoxiang Pharmaceutical Small Molecule Chemical Drug CDMO Introduction
11.8.4 Aoxiang Pharmaceutical Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.8.5 Aoxiang Pharmaceutical Recent Development
11.9 Hetero
11.9.1 Hetero Company Detail
11.9.2 Hetero Business Overview
11.9.3 Hetero Small Molecule Chemical Drug CDMO Introduction
11.9.4 Hetero Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.9.5 Hetero Recent Development
11.10 CellMark
11.10.1 CellMark Company Detail
11.10.2 CellMark Business Overview
11.10.3 CellMark Small Molecule Chemical Drug CDMO Introduction
11.10.4 CellMark Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.10.5 CellMark Recent Development
11.11 R&D Systems
11.11.1 R&D Systems Company Detail
11.11.2 R&D Systems Business Overview
11.11.3 R&D Systems Small Molecule Chemical Drug CDMO Introduction
11.11.4 R&D Systems Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.11.5 R&D Systems Recent Development
11.12 Porton Pharmaceuticals
11.12.1 Porton Pharmaceuticals Company Detail
11.12.2 Porton Pharmaceuticals Business Overview
11.12.3 Porton Pharmaceuticals Small Molecule Chemical Drug CDMO Introduction
11.12.4 Porton Pharmaceuticals Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.12.5 Porton Pharmaceuticals Recent Development
11.13 Kai Laiying
11.13.1 Kai Laiying Company Detail
11.13.2 Kai Laiying Business Overview
11.13.3 Kai Laiying Small Molecule Chemical Drug CDMO Introduction
11.13.4 Kai Laiying Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.13.5 Kai Laiying Recent Development
11.14 Smart Life
11.14.1 Smart Life Company Detail
11.14.2 Smart Life Business Overview
11.14.3 Smart Life Small Molecule Chemical Drug CDMO Introduction
11.14.4 Smart Life Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.14.5 Smart Life Recent Development
11.15 Notai Biotech
11.15.1 Notai Biotech Company Detail
11.15.2 Notai Biotech Business Overview
11.15.3 Notai Biotech Small Molecule Chemical Drug CDMO Introduction
11.15.4 Notai Biotech Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.15.5 Notai Biotech Recent Development
11.16 Aurobindo Pharma
11.16.1 Aurobindo Pharma Company Detail
11.16.2 Aurobindo Pharma Business Overview
11.16.3 Aurobindo Pharma Small Molecule Chemical Drug CDMO Introduction
11.16.4 Aurobindo Pharma Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.16.5 Aurobindo Pharma Recent Development
11.17 Lonza Group
11.17.1 Lonza Group Company Detail
11.17.2 Lonza Group Business Overview
11.17.3 Lonza Group Small Molecule Chemical Drug CDMO Introduction
11.17.4 Lonza Group Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.17.5 Lonza Group Recent Development
11.18 Catalent Inc.
11.18.1 Catalent Inc. Company Detail
11.18.2 Catalent Inc. Business Overview
11.18.3 Catalent Inc. Small Molecule Chemical Drug CDMO Introduction
11.18.4 Catalent Inc. Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.18.5 Catalent Inc. Recent Development
11.19 Recipharm AB
11.19.1 Recipharm AB Company Detail
11.19.2 Recipharm AB Business Overview
11.19.3 Recipharm AB Small Molecule Chemical Drug CDMO Introduction
11.19.4 Recipharm AB Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.19.5 Recipharm AB Recent Development
11.20 Jubilant Pharmova Ltd
11.20.1 Jubilant Pharmova Ltd Company Detail
11.20.2 Jubilant Pharmova Ltd Business Overview
11.20.3 Jubilant Pharmova Ltd Small Molecule Chemical Drug CDMO Introduction
11.20.4 Jubilant Pharmova Ltd Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.20.5 Jubilant Pharmova Ltd Recent Development
11.21 Patheon Inc. (Thermo Fisher Scientific Inc.)
11.21.1 Patheon Inc. (Thermo Fisher Scientific Inc.) Company Detail
11.21.2 Patheon Inc. (Thermo Fisher Scientific Inc.) Business Overview
11.21.3 Patheon Inc. (Thermo Fisher Scientific Inc.) Small Molecule Chemical Drug CDMO Introduction
11.21.4 Patheon Inc. (Thermo Fisher Scientific Inc.) Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.21.5 Patheon Inc. (Thermo Fisher Scientific Inc.) Recent Development
11.22 Boehringer Ingelheim Group
11.22.1 Boehringer Ingelheim Group Company Detail
11.22.2 Boehringer Ingelheim Group Business Overview
11.22.3 Boehringer Ingelheim Group Small Molecule Chemical Drug CDMO Introduction
11.22.4 Boehringer Ingelheim Group Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.22.5 Boehringer Ingelheim Group Recent Development
11.23 Pfizer CentreSource
11.23.1 Pfizer CentreSource Company Detail
11.23.2 Pfizer CentreSource Business Overview
11.23.3 Pfizer CentreSource Small Molecule Chemical Drug CDMO Introduction
11.23.4 Pfizer CentreSource Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.23.5 Pfizer CentreSource Recent Development
11.24 Baxter International Inc.
11.24.1 Baxter International Inc. Company Detail
11.24.2 Baxter International Inc. Business Overview
11.24.3 Baxter International Inc. Small Molecule Chemical Drug CDMO Introduction
11.24.4 Baxter International Inc. Revenue in Small Molecule Chemical Drug CDMO Business (2019-2024)
11.24.5 Baxter International Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Haixiang Pharmaceutical
Innovent Biologics
Betta Pharmaceuticals
Jiuzhou Pharmaceutical
Puluo Pharmaceutical
Menohua
Tianyu shares
Aoxiang Pharmaceutical
Hetero
CellMark
R&D Systems
Porton Pharmaceuticals
Kai Laiying
Smart Life
Notai Biotech
Aurobindo Pharma
Lonza Group
Catalent Inc.
Recipharm AB
Jubilant Pharmova Ltd
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource
Baxter International Inc.
听
听
*If Applicable.
